RecruitingNCT05100069

Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

General Use-results Survey of Alunbrig Tablets "Non-small Cell Lung Cancer"

Sponsor

Takeda

Enrollment

500 participants

Start Date

Nov 1, 2021

Study Type

OBSERVATIONAL

Conditions

Non-small Cell Lung Cancer (NSCLC)

Summary

This study is a survey in Japan of Brigatinib tablets used to treat Japanese people with non-small cell lung cancer. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related to lung disease from Brigatinib. During the study, participants with non-small cell lung cancer will take Brigatinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Brigatinib for 1 year.

Eligibility

Plain Language Summary

Simplified for easier understanding

This is a survey study collecting real-world information on how brigatinib is being used to treat people in Japan with ALK-positive non-small cell lung cancer (a type driven by a specific gene change). **You may be eligible if...** - You have been diagnosed with advanced or recurrent non-small cell lung cancer (NSCLC) that cannot be surgically removed - Your cancer tests positive for an ALK gene fusion - You are being treated with brigatinib as part of your standard care **You may NOT be eligible if...** - You have had a serious allergic reaction to brigatinib or any of its ingredients Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBrigatinib

Brigatinib Tablets

Locations(1)

Takeda Selected Site

Tokyo, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05100069

Related Trials

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT066944541 location

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

NCT0714001615 locations

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

NCT07361497254 locations

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

NCT07291037204 locations

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754156 locations